Concepedia

Author

Christiane Schuchardt

Zentralklinik Bad Berka

Also Known As

Christiane Schuchardt

49

Publications

2.5K

Citations

20

H-Index

43

Concepts

All Affiliations

Zentralklinik Bad BerkaNational University of SingaporeMaastricht UniversityJena University HospitalTechnical University of Munich
CS

About

Christiane Schuchardt is an author at Zentralklinik Bad Berka specializing in medicine, radiation oncology, and nuclear medicine.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

10

11

491

2

Health Sciences

7

7

234

3

Engineering

2

2

112

4

Immunology

1

1

14

5

Nephrology

1

1

20

Christiane Schuchardt

×

25

Publications

2.2K

Citations

18

H-Index

YearCitations

<sup>177</sup>Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy

Richard P. Baum, Harshad Kulkarni, Christiane Schuchardt,

Journal of Nuclear Medicine

2016

518

Molecular Imaging of <i>HER2</i>-Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic <sup>111</sup>In- or <sup>68</sup>Ga-Labeled Affibody Molecules

Richard P. Baum, Vikas Prasad, Dirk Müller,

Journal of Nuclear Medicine

2010

303

Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using <sup>177</sup>Lu-FAP-2286: First-in-Humans Results

Richard P. Baum, Christiane Schuchardt, Aviral Singh,

Journal of Nuclear Medicine

2021

287

Prostate-Specific Membrane Antigen Radioligand Therapy Using <sup>177</sup>Lu-PSMA I&amp;T and <sup>177</sup>Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry

Christiane Schuchardt, Jingjing Zhang, Harshad Kulkarni,

Journal of Nuclear Medicine

2021

164

First-in-Humans Application of <sup>161</sup>Tb: A Feasibility Study Using <sup>161</sup>Tb-DOTATOC

Richard P. Baum, Aviral Singh, Harshad Kulkarni,

Journal of Nuclear Medicine

2021

94

First-in-Humans Study of the SSTR Antagonist <sup>177</sup>Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy

Richard P. Baum, Jingjing Zhang, Christiane Schuchardt,

Journal of Nuclear Medicine

2021

93

Injection of Botulinum Toxin for Preventing Salivary Gland Toxicity after PSMA Radioligand Therapy: an Empirical Proof of a Promising Concept

Richard P. Baum, Thomas Langbein, Aviral Singh,

Nuclear Medicine and Molecular Imaging

2018

92

<sup>177</sup>Lu-3BP-227 for Neurotensin Receptor 1–Targeted Therapy of Metastatic Pancreatic Adenocarcinoma: First Clinical Results

Richard P. Baum, Aviral Singh, Christiane Schuchardt,

Journal of Nuclear Medicine

2017

83

The Bad Berka Dose Protocol: Comparative Results of Dosimetry in Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE, 177Lu-DOTANOC, and 177Lu-DOTATOC

Christiane Schuchardt, Harshad Kulkarni, Vikas Prasad,

Recent results in cancer research/Recent Results in Cancer Research

2012

69

Prognostic Value of <sup>18</sup>F-FDG PET/CT in a Large Cohort of Patients with Advanced Metastatic Neuroendocrine Neoplasms Treated with Peptide Receptor Radionuclide Therapy

Jingjing Zhang, Qingxing Liu, Aviral Singh,

Journal of Nuclear Medicine

2020

64

Page 1